In my role as Vice President, Oncology Business Unit, I am responsible for driving strategic and operational alignment across all oncology brands for AstraZeneca in Japan.

I have been leading the Oncology Business Unit and its portfolio since 2016. Most recently, I led three oncology launches including an EGFR TKI therapy (osimertinib), a PARP inhibitor (olaparib) and an immunotherapy (durvalumab) in Japan. These efforts have helped us achieve status as a top oncology business in Japan. 

I have spent nearly all my professional life at AstraZeneca. Over the past 30 years, I have built my career by taking increasing senior roles in marketing and specialty care. I led the first global launch of an EGFR-tyrosine kinase inhibitor (TKI) (gefitinib) in Japan and managed the company’s productive partnerships with Daiichi-Sankyo and Janssen Pharma. 

I received my degree in synthetic chemistry from Shinshu University, Faculty of Engineering in Nagano, Japan. 


I feel an enormous sense of achievement and reward when, as a team, we can bring differences to the real clinical practice of treating cancer patients.

Shin Morita Vice President, Oncology Business Unit


Vice President, Oncology Business Unit, AstraZeneca KK (Japan)

1990 - 2020

Served in various roles in marketing and specialty care at AstraZeneca KK (Japan)

1988 - 1990

Served as a medical representative at Imperial Chemical Industries


Awarded CEO award for the best launch of Tagrisso in Japan